When Wall Street’s “growth at any price” trading strategy cools down, capital tends to shift toward healthcare stocks that generate profits and cash flow. This pattern has repeated itself across monetary cycles over the past several decades. Currently, with the S&P 500 trading at elevated price-to-earnings multiples and earnings expectations heavily reliant on the technology sector, investors are beginning to look for less conspicuous targets with share prices around $50. Against this backdrop, a biotech company with defensive growth characteristics and what analysts see as further upside potential has come into focus.
Exelixis is an oncology-focused biotechnology company headquartered in Alameda, California, dedicated to discovering and commercializing targeted cancer therapies. Its most well-known product is CABOMETYX, used to treat kidney, liver, and thyroid cancers.
The company’s stock is currently trading near $50, up 12.05% over the past month and 14.15% year-to-date. Fundamentals support this stock performance. In the first quarter of 2026, Exelixis reported non-GAAP earnings per share of $0.87, beating consensus estimates by 14.02%; revenue came in at $610.81 million, a year-over-year increase of 9.97%. Operating profit grew 34.51%, and net income rose 31.86%. This marks the fourth consecutive quarter in which the company has exceeded earnings expectations, with surprise margins ranging from 14.02% to 17.17%.
The stock has a trailing price-to-earnings ratio of 17 and a forward P/E of 16. Analysts have set a price target of $49.65, with ratings comprising 1 Strong Buy, 9 Buys, and 9 Holds. H.C. Wainwright rates the stock a “Buy” with a price target of $54.
The logic supporting the stock’s upside is very clear. CABOMETYX is the most prescribed TKI in the renal cell carcinoma space, and global revenue for its CABOMETYX franchise grew 12.5% year-over-year in the first quarter, reaching $764 million. Management holds approximately $1.4 billion in cash and marketable securities and, after completing a previous $750 million share repurchase program, has authorized a new $750 million buyback plan running through December 31, 2027. More importantly, the PDUFA (Prescription Drug User Fee Act) review date for zanzalintinib, intended for previously treated metastatic colorectal cancer, is set for December 3, 2026. Exelixis CEO Michael Morrissey has called this “the highest priority for the entire company,” with the market opportunity for this indication estimated at approximately $1.5 billion. The company has provided total revenue guidance for fiscal 2026 of $2.525 billion to $2.625 billion, which explicitly excludes any contribution from the launch of zanzalintinib, leaving upside room for future performance.
The main risk lies in product concentration. The CABOMETYX franchise still contributes the vast majority of revenue. Any regulatory delay or rejection of zanzalintinib would remove the most closely watched near-term catalyst. Previous disappointing clinical trial results have also served as a reminder that “triplet therapy in clear cell renal cell carcinoma is no easy feat.” Additionally, the potential generic competition facing CABOMETYX toward the end of this decade remains a concern.
With a beta of 0.385, a profitable operating profile, an active share repurchase program, and a key regulatory milestone approaching in December, Exelixis exhibits the classic characteristics of a cash-generating oncology company. Historical experience suggests that when defensive healthcare stocks regain market favor, companies like this one are well positioned to benefit.
